- |||||||||| Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement? (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=88, Active, not recruiting, Recruiting --> Completed Recruiting --> Active, not recruiting | N=48 --> 88 | Trial completion date: Nov 2018 --> Jun 2019 | Trial primary completion date: Oct 2018 --> Sep 2017
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response (clinicaltrials.gov) - May 4, 2018
P=N/A, N=570, Completed, Trial completion date: Apr 2018 --> Sep 2018 | Trial primary completion date: Apr 2018 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Apr 2018 | Trial primary completion date: Jan 2020 --> Apr 2018
- |||||||||| oxaliplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial withdrawal, Metastases: Combination Treatment for Advanced Liver Cancer (clinicaltrials.gov) - Apr 19, 2018 P3, N=0, Withdrawn, Recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2018 N=98 --> 0 | Completed --> Withdrawn
- |||||||||| Trial completion, Trial completion date: Study for Consolidation Period of Chronic Hepatitis B (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=137, Completed, N=63 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Apr 2018
- |||||||||| ITX-5061 / iTherX
Trial completion date, Trial termination, Trial primary completion date: Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection (clinicaltrials.gov) - Apr 18, 2018 P1, N=10, Terminated, Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Apr 2018 Trial completion date: Oct 2017 --> Apr 2018 | Active, not recruiting --> Terminated | Trial primary completion date: May 2017 --> Apr 2018; Financial Reasons
- |||||||||| Trial completion, Phase classification, Trial completion date, IO biomarker: The Pathogenesis of Hepatitis C Virus Vertical Transmission (clinicaltrials.gov) - Apr 9, 2018
P, N=38, Completed, Completed --> Terminated; inability to obtain CMS approval Recruiting --> Completed | Phase classification: PN/A --> P | Trial completion date: Dec 2018 --> Dec 2017
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Terlipressin Administration in Patients Undergoing Major Liver Resection (clinicaltrials.gov) - Mar 27, 2018
P2, N=150, Terminated, Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Jun 2017 N=348 --> 150 | Trial completion date: Apr 2019 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Mar 2018
- |||||||||| omeprazole / Generic mfg.
Trial completion date, Trial primary completion date: Proton Pump Inhibitors and Dysbiosis in Cirrhosis (clinicaltrials.gov) - Mar 19, 2018 P=N/A, N=60, Completed, N=6000 --> 0 Trial completion date: Nov 2013 --> Feb 2018 | Trial primary completion date: Nov 2013 --> Feb 2018
- |||||||||| sorafenib / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date: Sorafenib for Hepatopulmonary Syndrome (clinicaltrials.gov) - Mar 15, 2018 P2, N=28, Terminated, Trial completion date: Nov 2013 --> Feb 2018 | Trial primary completion date: Nov 2013 --> Feb 2018 Trial completion date: Jun 2018 --> Jan 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Jan 2018
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=43, Terminated, Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Nov 2016 N=300 --> 43 | Trial completion date: Dec 2019 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2018; FDA released requirement to complete study
- |||||||||| Trial completion date, Trial termination, Trial primary completion date: Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization (clinicaltrials.gov) - Mar 5, 2018
P1, N=57, Terminated, N=165 --> 57 | Recruiting --> Terminated; Low inclusion rate Trial completion date: Jun 2018 --> Apr 2017 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Apr 2017; Logistics regarding PET/CT portion of study
- |||||||||| floxuridine / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Surgery, Metastases: Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery (clinicaltrials.gov) - Feb 20, 2018 P1/2, N=16, Completed, Recruiting --> Completed | N=50 --> 34 | Trial completion date: Dec 2017 --> Sep 2017 | Trial primary completion date: Dec 2017 --> Sep 2017 Active, not recruiting --> Completed | N=28 --> 16 | Trial primary completion date: Jul 2018 --> Feb 2018 | Trial completion date: Jul 2018 --> Feb 2018
- |||||||||| entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy: IN-US-0205: Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B (clinicaltrials.gov) - Feb 20, 2018 P4, N=102, Completed, Active, not recruiting --> Completed | N=28 --> 16 | Trial primary completion date: Jul 2018 --> Feb 2018 | Trial completion date: Jul 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2017 | Trial completion date: Feb 2018 --> Sep 2017 | Initiation date: Sep 2012 --> Sep 2012
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: AVAMET: Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer (clinicaltrials.gov) - Feb 19, 2018 P4, N=83, Completed, Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2017 | Trial completion date: Feb 2018 --> Sep 2017 | Initiation date: Sep 2012 --> Sep 2012 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2014 | Trial completion date: Dec 2017 --> Dec 2017 | Initiation date: Nov 2011 --> Nov 2011
- |||||||||| sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 14, 2018 P2/3, N=86, Completed, Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2014 | Trial completion date: Dec 2017 --> Dec 2017 | Initiation date: Nov 2011 --> Nov 2011 Recruiting --> Completed
- |||||||||| Phase classification, Enrollment change, Trial termination, Trial primary completion date, Surgery: Clinical Application of Image-Guided Liver Surgery (clinicaltrials.gov) - Feb 13, 2018
P2, N=40, Terminated, Recruiting --> Completed Phase classification: P=N/A --> P2 | N=66 --> 40 | Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> May 2011; The image-guidance system became commercially available
- |||||||||| Enrollment change, Trial withdrawal, Trial primary completion date: Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer (clinicaltrials.gov) - Feb 1, 2018
P1, N=0, Withdrawn, Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 N=24 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Sep 2014 --> Feb 2016
|